EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis

Yahao Wang iD, Yue Zhou, Zhihong Wang, Yunzhi Ni, Gerald J Prud'homme, Qinghua Wang iD

The Journal of Clinical Endocrinology & Metabolism · 16.09.2025 · 110 (10) · 2964-2979

DOI: 10.1210/clinem/dgaf336 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 09.06.2025. Verfasst von Yahao Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai 200040, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Fatty Liver, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 92 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

New therapies are urgently needed for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). We conducted this systematic review and meta-analysis to evaluate the therapeutic effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on MASLD/MASH.

Methods

We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH. The effects of GLP-1RAs on liver fat content (LFC) by imaging, liver histology, serum liver enzymes, and noninvasive fibrosis indexes [Fibrosis-4, nonalcoholic fatty liver disease fibrosis score, cytokeratin 18, procollagen III, and liver stiffness) were evaluated. Mean differences and risk ratios with 95% confidence intervals were pooled using a random-effect model.

Results

Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included. Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%, with retatrutide displaying the most obvious treatment effects. GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation but nonsignificantly improved fibrosis, with the evidence for tirzepatide more robust than that for semaglutide and liraglutide. GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control. GLP-1RAs also significantly improved liver stiffness, with semaglutide displaying the most obvious treatment effect. No drug-related adverse effects involving the liver were observed.

Conclusion

GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsFatty LiverNon-alcoholic Fatty Liver DiseaseMetabolic DiseasesGlucagon-Like Peptide 1Hypoglycemic AgentsHumansRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

GLP-1MASHliver biopsyliver fat content

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Hypoglycemic Agents

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai 200040, China.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada M5B 1W8.
  • Shanghai Innogen Pharmaceutical Co., Ltd., Shanghai 201203, China.

ORCID-Profile: Yahao Wang, Qinghua Wang

Förderung

  • National Natural Science Foundation of China
  • Ministry of Science and Technology

Zitieren

APA

Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud'homme, G. J., & Wang, Q. (2025). Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis. The Journal of Clinical Endocrinology & Metabolism, 110(10), 2964-2979. https://doi.org/10.1210/clinem/dgaf336

Vancouver

Wang Y, Zhou Y, Wang Z, Ni Y, Prud'homme GJ, Wang Q. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2025;110(10):2964-2979. doi:10.1210/clinem/dgaf336

BibTeX
@article{Wang2025,
  author = {Wang, Yahao and Zhou, Yue and Wang, Zhihong and Ni, Yunzhi and Prud'homme, Gerald J and Wang, Qinghua},
  title = {Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {10},
  pages = {2964--2979},
  doi = {10.1210/clinem/dgaf336}
}
Kostenlos starten →